natgillin/translations-raw huggingface dataset:
disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paresthaesia neuroleptic malignant syndrome, cerebral ischaemia, unresponsive to stimuli c, loss of consciousness, depressed level of consciousness c, 
svimning, psykomotorisk hyperaktivitet, postural yrsel, uppmärksamhetsstörning, dysartri, dysgeusi, hypoestesi, parestesi malignt neuroleptikasyndrom, cerebral ischemi, avsaknad av respons på stimuli, medvetandeförlust c,
• problems with speech 
• talsvårigheter
White polyvinyl chloride (PVC) laminated with polychloro-trifluoroethylene (PCTFE)/aluminium push-through layer. 
Vit polyvinylkloridlaminerad (PVC) med folieskikt av polyklortrifluoreten (PCTFE)/aluminium.
The adverse drug reactions (ADRs) most frequently reported in clinical trials with adults were headache, insomnia, sedation/somnolence, parkinsonism, akathisia, tachycardia, tremor, dystonia, upper respiratory tract infection, anxiety, dizziness, weight increased, nausea, agitation, constipation, vomiting, fatigue, depression, dyspepsia, diarrhoea, dry mouth, toothache, musculoskeletal pain, hypertension, asthenia, back pain, electrocardiogram QT prolonged, and cough. 
De mest rapporterade biverkningarna i kliniska prövningar med vuxna var huvudvärk, insomni, sedering/somnolens, parkinsonism, akatisi, takykardi, tremor, dystoni, övre luftvägsinfektion, ångest, yrsel, viktuppgång, illamående, agitation, förstoppning, kräkningar, trötthet, depression, dyspepsi, diarré, muntorrhet, tandvärk, muskuloskeletal smärta, hypertension, asteni, ryggsmärta, QTförlängning på EKG och hosta.
When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 4 days. 
Då dosökning är indicerad rekommenderas stegvisa ökningar om 3 mg/dag, vilka generellt inte bör göras oftare än var 4:e dag.
• a blockage in the bowels, stool incontinence, very hard stool, lack of bowel muscle movement that causes blockage 
• stopp i tarmen, avföringsinkontinens, mycket hård avföring, avsaknad av tarmmuskelrörelser
- Bottles: The tablets are supplied in a plastic bottle with a child-resistant plastic cap. Each bottle contains either 30 tablets or 350 tablets. 
- Burkar: Tabletterna tillhandahålls i en plastburk med ett barnskyddande plastlock.
14 prolonged-release tablets 28 prolonged-release tablets 49 prolonged-release tablets 56 prolonged-release tablets 98 prolonged-release tablets 
14 depottabletter 28 depottabletter 49 depottabletter 56 depottabletter 98 depottabletter
Polyvinyl chloride (PVC) laminated with polychloro-trifluoroethylene (PCTFE)/aluminium push-through layer. 
Polyvinylkloridlaminerad (PVC) med folieskikt av polyklortrifluoreten (PCTFE)/aluminium.
Schizophrenia Studies: Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score - Change From Baseline to End Point - LOCF for Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305: Intent-to-Treat Analysis Set 
Schizofrenistudier: Totalpoäng på Positive and Negative Syndrome Scale for Schizophrenia (PANSS)förändring från baslinjevärde till effektmått-LOCF för studierna R076477-SCH-303, R076477-SCH-304 och R076477-SCH-305: Intent-to-Treat-analys
BOTTLE CARTON 
KARTONG FÖR BURK
Iron oxide (black) (E172) Propylene glycol Hypromellose 
Järnoxid (svart) (E172) Propylenglykol Hypromellos
pollakiuria, urinary retention, dysuria 
Njurar och urinvägar urininkontinens, pollakisuri, urinretention, dysuri
Musculoskelet al and connective tissue disorders musculoskeletal pain, back pain, arthralgia blood creatine phosphokinase increased, muscle spasms, joint stiffness, joint swelling, muscular weakness, neck pain rhabdomyolysis c, posture abnormal 
Muskuloskeletala systemet och bindväv muskuloskeletal smärta, ryggsmärta, artralgi ökat kreatinfosfokinas i blod, muskelspasmer, ledstelhet, ledsvullnad, muskelsvaghet, nacksmärta rabdomyolys c, onormal hållning
14 prolonged-release tablets 28 prolonged-release tablets 30 prolonged-release tablets 49 prolonged-release tablets 56 prolonged-release tablets 98 prolonged-release tablets 
14 depottabletter 28 depottabletter 30 depottabletter 49 depottabletter 56 depottabletter 98 depottabletter
When symptoms of high prolactin occur, they may include: (in men) breast swelling, difficulty in getting or maintaining erections, or other sexual dysfunction, (in women) breast discomfort, leakage of milk from the breasts, missed menstrual periods, or other problems with your cycle. 
Hos kvinnor kan symtomen vara obehag från brösten, mjölkläckage, missade menstruationsperioder eller andra problem med menstruationscykeln.
Paliperidone 
Depottablett
dry mouth, toothache 
• halsont, hosta, nästäppa
When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days. 
Då dosökning är indicerad rekommenderas stegvisa ökningar om 3 mg/dag, vilka generellt inte bör göras oftare än var 5:e dag.
Mean baseline (SD) Mean change (SD) P-value (vs, Placebo) Diff. of LS Means (SE) 
Genomsnittligt baslinjevärde (SD) Genomsnittlig förändring (SD) P-värde (vs placebo) Skillnad mellan minsta kvadratmedelvärden (SE)
conjunctivitis, dry eye glaucoma, eye movement disorder c, 
Dimsyn fotofobi, konjunktivit, torra ögon glaukom, ögonrörelsestörningar c, ögonrullningar c,
Hydroxyethyl Cellulose Polyethylene glycol 3350 
Polyetylenglykol 3350
INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets paliperidone 
INVEGA 3 mg depottabletter INVEGA 6 mg depottabletter INVEGA 9 mg depottabletter INVEGA 12 mg depottabletter paliperidon
• pneumonia, infection of the breathing passages, bladder infection, ear infection, tonsillitis 
• lunginflammation, luftvägsinfektion, infektion i urinblåsan, öroninfektion, halsfluss
Skin and subcutaneous tissue disorders pruritus, rash urticaria, alopecia, eczema, acne angioedema, drug eruption c, hyperkeratosis, dry skin, erythema, skin discolouration, seborrhoeic dermatitis, dandruff 
Hud och subkutan vävnad pruritus, utslag urtikaria, alopeci, eksem, akne angioödem, läkemedelsutslag c, hyperkeratos, torr hud, erytem, missfärgning av hud, seborroisk dermatit, mjäll
Rare side effects: may affect up to 1 in 1,000 people 
Sällsynta (förekommer hos färre än 1 av 1000 användare):
The recommended dose of INVEGA for the treatment of schizophrenia in adults is 6 mg once daily, administered in the morning. 
Den rekommenderade dosen av INVEGA för behandling av schizofreni hos vuxna är 6 mg en gång per dag, med intag på morgonen.
waist circumference increased, anorexia, blood triglycerides increased water intoxication, diabetic ketoacidosis c, hypoglycaemia, polydipsia, blood cholesterol increased hyperinsulinaemi 
Metabolism och nutrition viktökning, aptitökning, viktminskning, aptitminskning diabetes mellitus d, hyperglykemi, ökat midjemått, anorexi, ökade triglycerider vattenförgiftning, diabetisk ketoacidos c, hypoglykemi, polydipsi, ökat kolesterol hyperinsulinemi
• chest pain, chest discomfort, feeling unwell 
• smärta i bröstkorgen, obehagskänsla i bröstkorgen, sjukdomskänsla
In a 40-week juvenile toxicity study in dogs with oral doses of risperidone (which is extensively converted to paliperidone) up to 5 mg/kg/day, effects on sexual maturation, long bone growth and femur mineral density were observed from 3 times the clinical exposure based on AUC. 
I en 40 veckors toxicitetsstudie på unga hundar med orala doser av risperidon (som i stor omfattning omvandlas till paliperidon) upp till 5 mg/kg/dag,
confusional state, libido decreased, anorgasmia, nervousness, nightmare catatonia, somnambulism, blunted affect 
Psykiska störningar insomni mani, agitation, depression, ångest sömnproblem, förvirringstillstånd, minskad libido, anorgasmi, nervositet, mardrömmar katatoni, somnambulism, känslomässig avtrubbning
How to store INVEGA 
Hur INVEGA ska förvaras
Schizophrenia Studies: Proportion of Subjects with Responder Status at LOCF End Point Studies R076477-SCH-303, R076477-SCH-304, and R076477-SCH-305: Intent-to-Treat Analysis Set 
Schizofrenistudier: Andel individer med responderstatus för effektmått-LOCF Studier R076477-SCH-303, R076477-SCH-304 och R076477-SCH-305: Intent-to-Treat-analys Placebo INVEGA 3 mg
• eye infection, fungal infection of the nails, infection of the skin, skin inflammation caused by mites 
• ögoninfektion, nagelsvamp, hudinfektion, hudinflammation orsakad av kvalster
The recommended dose of INVEGA for the treatment of schizoaffective disorder in adults is 6 mg once daily, administered in the morning. 
Den rekommenderade dosen av INVEGA för behandling av schizoaffektivt syndrom hos vuxna är 6 mg en gång per dag, med intag på morgonen.
flatulence pancreatitis c, 
nedsatt medvetandegrad c,
depression, anxiety sleep disorder, 
Psykiska störningar: sömnrelaterad ätstörning
Trilayer capsule-shaped white tablets of 11 mm in length and 5 mm in diameter printed with “PAL 3” Trilayer capsule-shaped beige tablets of 11 mm in length and 5 mm in diameter printed with “PAL 6” Trilayer capsule-shaped pink tablets of 11 mm in length and 5 mm in diameter printed with “PAL 9” Trilayer capsule-shaped yellow tablets of 11 mm in length and 5 mm in diameter printed with “PAL 12” 
Kapselformad beige treskiktstablett, 11 mm lång och 5 mm i diameter, märkt ”PAL 6”.
The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet. 
Tablettskalet, jämte olösliga beståndsdelar i tablettkärnan, elimineras från kroppen.
INVEGA 3 mg prolonged-release tablets INVEGA 6 mg prolonged-release tablets INVEGA 9 mg prolonged-release tablets INVEGA 12 mg prolonged-release tablets 
INVEGA 3 mg depottabletter INVEGA 6 mg depottabletter INVEGA 9 mg depottabletter INVEGA 12 mg depottabletter
Schizoaffective Disorder Studies: Primary Efficacy Parameter, PANSS Total Score Change from Baseline from Studies R076477-SCA-3001 and R076477-SCA-3002: Intent-to-Treat Analysis Set 
Studier av schizoaffektivt syndrom: Primärt effektmått, Förändring av total PANSS-poäng från baslinjen från studie R076477-SCA-3001 och R076477-SCA-3002: Intent-to-Treat-analys
Butyl hydroxytoluene (E321) Ferric Oxide (Yellow) (E172) (3, 12 mg tablet only) Polyethylene Oxide 7000K Ferric Oxide (Red) (E172) 
Butylhydroxitoluen (E321) Järnoxid (gul) (E172) (endast 3 och 12 mg-tabletten) Polyetylenoxid 7000K
Schizoaffective Disorder Studies: Secondary Efficacy Parameter, Proportion of Subjects with Responder Status at LOCF End Point: Studies R076477-SCA-3001 and R076477-SCA-3002: Intent-to-Treat Analysis Set 
Studier av schizoaffektivt syndrom: Sekundärt effektmått, Andel individer med responderstatus vid effektmått-LOCF: Studier R076477-SCA-3001 och R076477-SCA-3002: Intent-to-Treat-analys
• infection of the chest (bronchitis), common cold symptoms, sinus infection, urinary tract infection, feeling like you have the flu 
• infektion i luftvägarna (bronkit), förkylningssymtom, bihåleinflammation, urinvägsinfektion,
Medicines with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical, involuntary movements, predominantly of the tongue and/or face. 
Läkemedel med dopaminreceptorantagonistiska egenskaper har satts i samband med framkallande av tardiv dyskinesi.
hyperglycaemia, 
Hydroxietylcellulosa
Printing ink Iron oxide (black) (E172) 
Märkbläck: Järnoxid (svart) (E172)
Uncommon side effects: may affect up to 1 in 100 people 
Mindre vanliga (förekommer hos färre än 1 av 100 användare):
In all three studies, INVEGA was superior to placebo on PSP and CGI-S. Efficacy was also evaluated by calculation of treatment response (defined as decrease in PANSS Total Score ≥ 30%) as a secondary endpoint. 
Effekten utvärderades också genom att beräkna behandlingssvar (definieras som en minskning i total PANSSpoäng  30 %) som sekundärt effektmått.
Mean baseline (SD) Mean change (SD) P-value (vs. 
Genomsnittligt baslinjevärde (SD)
• hives (or “nettle rash”), hair loss, eczema, acne 
• utslag (nässelutslag), håravfall, eksem, akne
Withdrawal of INVEGA may be needed. 
Behandlingen med INVEGA kan behöva avslutas.
Vascular disorders orthostatic hypotension, hypertension hypotension pulmonary embolism, venous thrombosis, 
Hypotension lungembolism, venös trombos, ischemi, flushing
General disorders pyrexia, asthenia, fatigue face oedema, oedema e, chills, body temperature increased, gait abnormal, thirst, chest pain, chest discomfort, malaise hypothermia c, body temperature decreased c, drug withdrawal syndrome induration 
Allmänna symtom och/eller symtom vid administrering sstället pyrexi, asteni, utmattning ansiktsödem, ödem e, frossa, ökad kroppstemperatur, onormal gång, ökad törst, bröstkorgssmärta, obehag i bröstkorgen, sjukdomskänsla hypotermi c,
• abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhoea, indigestion, 
• obehag eller smärta från buken, kräkningar, illamående, förstoppning, diarré, magbesvär, torr mun, tandvärk
Each prolonged-release tablet contains 9 mg of paliperidone. 
Varje depottablett innehåller 9 mg paliperidon.
Hypromellose Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (red) (E172) Carnauba wax 
Hypromellos Titandioxid (E171) Polyetylenglykol 400 Järnoxid (röd) (E172) Karnaubavax
Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (yellow) (E172) Carnauba wax 
Hypromellos Titandioxid (E171) Polyetylenglykol 400 Järnoxid (gul) (E172) Karnaubavax
Each INVEGA 9 mg prolonged-release tablet contains 9 mg of paliperidone. 
Varje INVEGA 9 mg depottablett innehåller 9 mg paliperidon.
• lung congestion 
• näsblödningar
Each prolonged-release tablet contains 3 mg of paliperidone. 
Varje depottablett innehåller 3 mg paliperidon.
Cardiac disorders atrioventricular block, conduction disorder, electrocardiogra m QT prolonged, bradycardia, 
Hjärtat atrioventrikulärt block, retledningsstörningar, QTförlängning på EKG, bradykardi, takykardi sinusarytmi, onormalt EKG, palpitationer förmaksflimmer, posturalt ortostatiskt takykardisyndrom
Each prolonged-release tablet contains 12 mg of paliperidone. 
Varje depottablett innehåller 12 mg paliperidon.
hypersensitivity 
Fuktkänsligt
30 prolonged-release tablets - EU/1/07/395/057 350 prolonged-release tablets - EU/1/07/395/058 
30 depottabletter - EU/1/07/395/057 350 depottabletter - EU/1/07/395/058
headache dystonia b, dizziness, dyskinesia b, 
Centrala och perifera nervsystemet parkinsonism b, akatisi b, sedation/ somnolens, huvudvärk dystoni b, yrsel, dyskinesi b,
30 prolonged-release tablets - EU/1/07/395/063 350 prolonged-release tablets - EU/1/07/395/064 
30 depottabletter - EU/1/07/395/063 350 depottabletter - EU/1/07/395/064
Each INVEGA 12 mg prolonged-release tablet contains 12 mg of paliperidone. 
Varje INVEGA 12 mg depottablett innehåller 12 mg paliperidon.
Each INVEGA 6 mg prolonged-release tablet contains 6 mg of paliperidone. 
Varje INVEGA 6 mg depottablett innehåller 6 mg paliperidon.
30 prolonged-release tablets - EU/1/07/395/061 350 prolonged-release tablets - EU/1/07/395/062 
30 depottabletter - EU/1/07/395/061 350 depottabletter - EU/1/07/395/062
Each prolonged-release tablet contains 6 mg of paliperidone. 
Varje depottablett innehåller 6 mg paliperidon.
Hepatic impairment 
influensaliknande känsla
30 prolonged-release tablets - EU/1/07/395/059 350 prolonged-release tablets - EU/1/07/395/060 
30 depottabletter - EU/1/07/395/059 350 depottabletter - EU/1/07/395/060
• missed menstrual periods or other problems with your cycle (females), leakage of milk from the breasts, sexual dysfunction, breast pain, breast discomfort 
• uteblivna menstruationsperioder eller andra problem med menstruationscykeln (kvinnor),
Overcoat 
Kramper
14 prolonged-release tablets - EU/1/07/395/074 - CLEAR 28 prolonged-release tablets - EU/1/07/395/016 - CLEAR 30 prolonged-release tablets - EU/1/07/395/017 - CLEAR 49 prolonged-release tablets - EU/1/07/395/018 - CLEAR 56 prolonged-release tablets - EU/1/07/395/019 - CLEAR 98 prolonged-release tablets - EU/1/07/395/020 - CLEAR 
14 depottabletter - EU/1/07/395/074 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/016 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/017 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/018 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/019 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/020 - GENOMSKINLIG
14 prolonged-release tablets - EU/1/07/395/070 28 prolonged-release tablets - EU/1/07/395/045 49 prolonged-release tablets - EU/1/07/395/046 56 prolonged-release tablets - EU/1/07/395/047 98 prolonged-release tablets - EU/1/07/395/048 
14 depottabletter - EU/1/07/395/070 28 depottabletter - EU/1/07/395/045 49 depottabletter - EU/1/07/395/046 56 depottabletter - EU/1/07/395/047 98 depottabletter - EU/1/07/395/048
14 prolonged-release tablets - EU/1/07/395/071 - CLEAR 28 prolonged-release tablets - EU/1/07/395/011 - CLEAR 30 prolonged-release tablets - EU/1/07/395/012 - CLEAR 49 prolonged-release tablets - EU/1/07/395/013 - CLEAR 56 prolonged-release tablets - EU/1/07/395/014 - CLEAR 98 prolonged-release tablets - EU/1/07/395/015 - CLEAR 
14 depottabletter - EU/1/07/395/071 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/011 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/012 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/013 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/014 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/015 - GENOMSKINLIG
EU/1/07/395/001 - 005 EU/1/07/395/021 - 025 EU/1/07/395/041 - 044 EU/1/07/395/057 - 058 EU/1/07/395/065 - 067 
EU/1/07/395/041 - 044 EU/1/07/395/057 - 058 EU/1/07/395/065 - 067
Each INVEGA 3 mg prolonged-release tablet contains 3 mg of paliperidone. 
Den aktiva substansen är paliperidon Varje INVEGA 3 mg depottablett innehåller 3 mg paliperidon.
14 prolonged-release tablets - EU/1/07/395/076 28 prolonged-release tablets - EU/1/07/395/053 49 prolonged-release tablets - EU/1/07/395/054 56 prolonged-release tablets - EU/1/07/395/055 98 prolonged-release tablets - EU/1/07/395/056 
14 depottabletter - EU/1/07/395/076 28 depottabletter - EU/1/07/395/053 49 depottabletter - EU/1/07/395/054 56 depottabletter - EU/1/07/395/055 98 depottabletter - EU/1/07/395/056
14 prolonged-release tablets - EU/1/07/395/067 28 prolonged-release tablets - EU/1/07/395/041 49 prolonged-release tablets - EU/1/07/395/042 56 prolonged-release tablets - EU/1/07/395/043 98 prolonged-release tablets - EU/1/07/395/044 
14 depottabletter - EU/1/07/395/067 28 depottabletter - EU/1/07/395/041 49 depottabletter - EU/1/07/395/042 56 depottabletter - EU/1/07/395/043 98 depottabletter - EU/1/07/395/044
14 prolonged-release tablets - EU/1/07/395/073 28 prolonged-release tablets - EU/1/07/395/049 49 prolonged-release tablets - EU/1/07/395/050 56 prolonged-release tablets - EU/1/07/395/051 98 prolonged-release tablets - EU/1/07/395/052 
14 depottabletter - EU/1/07/395/073 28 depottabletter - EU/1/07/395/049 49 depottabletter - EU/1/07/395/050 56 depottabletter - EU/1/07/395/051 98 depottabletter - EU/1/07/395/052
14 prolonged-release tablets - EU/1/07/395/065 - CLEAR 28 prolonged-release tablets - EU/1/07/395/001 - CLEAR 30 prolonged-release tablets - EU/1/07/395/002 - CLEAR 49 prolonged-release tablets - EU/1/07/395/003 - CLEAR 56 prolonged-release tablets - EU/1/07/395/004 - CLEAR 98 prolonged-release tablets - EU/1/07/395/005 - CLEAR 
14 depottabletter - EU/1/07/395/065 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/001 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/002 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/003 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/004 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/005 - GENOMSKINLIG
14 prolonged-release tablets - EU/1/07/395/068 - CLEAR 28 prolonged-release tablets - EU/1/07/395/006 - CLEAR 30 prolonged-release tablets - EU/1/07/395/007 - CLEAR 49 prolonged-release tablets - EU/1/07/395/008 - CLEAR 56 prolonged-release tablets - EU/1/07/395/009 - CLEAR 98 prolonged-release tablets - EU/1/07/395/010 - CLEAR 
14 depottabletter - EU/1/07/395/068 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/006 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/007 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/008 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/009 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/010 - GENOMSKINLIG
14 prolonged-release tablets - EU/1/07/395/075 - WHITE 28 prolonged-release tablets - EU/1/07/395/036 - WHITE 30 prolonged-release tablets - EU/1/07/395/037 - WHITE 49 prolonged-release tablets - EU/1/07/395/038 - WHITE 56 prolonged-release tablets - EU/1/07/395/039 - WHITE 98 prolonged-release tablets - EU/1/07/395/040 - WHITE 
14 depottabletter - EU/1/07/395/075 - VIT 28 depottabletter - EU/1/07/395/036 - VIT 30 depottabletter - EU/1/07/395/037 - VIT 49 depottabletter - EU/1/07/395/038 - VIT 56 depottabletter - EU/1/07/395/039 - VIT 98 depottabletter - EU/1/07/395/040 - VIT
• stomach pain 
• dimsyn
14 prolonged-release tablets - EU/1/07/395/066 - WHITE 28 prolonged-release tablets - EU/1/07/395/021 - WHITE 30 prolonged-release tablets - EU/1/07/395/022 - WHITE 49 prolonged-release tablets - EU/1/07/395/023 - WHITE 56 prolonged-release tablets - EU/1/07/395/024 - WHITE 98 prolonged-release tablets - EU/1/07/395/025 - WHITE 
14 depottabletter - EU/1/07/395/066 - VIT 28 depottabletter - EU/1/07/395/021 - VIT 30 depottabletter - EU/1/07/395/022 - VIT 49 depottabletter - EU/1/07/395/023 - VIT 56 depottabletter - EU/1/07/395/024 - VIT 98 depottabletter - EU/1/07/395/025 - VIT
You should be aware that both of these conditions may be caused by this type of medicine. 
• om du någon gång har haft avvikande rörelser i tunga eller ansikte (tardiv dyskinesi).Du bör känna till att båda dessa tillstånd kan orsakas av denna typ av läkemedel.
Core 
Kön
Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate 
Butylhydroxitoluen (E321) Polyetylenoxid 7000K Järnoxid (röd) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
14 prolonged-release tablets - EU/1/07/395/072 - WHITE 28 prolonged-release tablets - EU/1/07/395/031 - WHITE 30 prolonged-release tablets - EU/1/07/395/032 - WHITE 49 prolonged-release tablets - EU/1/07/395/033 - WHITE 56 prolonged-release tablets - EU/1/07/395/034 - WHITE 98 prolonged-release tablets - EU/1/07/395/035 - WHITE 
14 depottabletter - EU/1/07/395/072 - VIT 28 depottabletter - EU/1/07/395/031 - VIT 30 depottabletter - EU/1/07/395/032 - VIT 49 depottabletter - EU/1/07/395/033 - VIT 56 depottabletter - EU/1/07/395/034 - VIT 98 depottabletter - EU/1/07/395/035 - VIT
Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Ferric oxide (yellow) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate 
Butylhydroxitoluen (E321) Polyetylenoxid 7000K Järnoxid (röd) (E172) Järnoxid (gul) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Iron oxide (black) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate 
Butylhydroxitoluen (E321) Polyetylenoxid 7000K Järnoxid (röd) (E172) Järnoxid (svart) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
Butyl hydroxytoluene (E321) Ferric oxide (yellow) (E172) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate 
Butylhydroxitoluen (E321) Järnoxid (gul) (E172) Polyetylenoxid 7000K Järnoxid (röd) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
LOCF endpoint change from baseline 
Förändring från baslinjevärde till effektmått-LOCF.
Placebo) Diff. of LS Means (SE) 
P-värde (vs placebo)
Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, Marketing Authorisation Holders in the Member States 
Bilaga I Förteckning över läkemedlets namn, läkemedelsform, styrka, administreringssätt av läkemedlet samt innehavare av godkännande för försäljning i medlemsstaterna
Heinzelova 62a 10 000 Zagreb Croatia 
Heinzelova 62a 10 000 Zagreb Kroatien